Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction  by Ernst, Nicolette M.S.K.J. et al.
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chieved Platelet Aggregation Inhibition
fter Different Antiplatelet Regimens
uring Percutaneous Coronary Intervention
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OBJECTIVES To evaluate the extent of platelet aggregation inhibition in patients with ST-segment
elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention
(PCI), treated with different antiplatelet agents and dosages.
BACKGROUND The extent of platelet aggregation inhibition is an independent predictor of major cardiac
events after elective PCI. In STEMI patients undergoing PCI, routine dose of antiplatelet
agents may be associated with less effective platelet aggregation inhibition.
METHODS Patients were treated with clopidogrel before angiography and randomized to abciximab,
tirofiban, high-dose tirofiban, or no glycoprotein (GP) IIb/IIIa inhibitor; GP IIb/IIIa
inhibitor bolus, followed by maintenance infusion, was administered after angiography, but
before PCI. Platelet aggregation inhibition was assessed before angiography, immediately
after PCI, and 1 and 6 h afterwards.
RESULTS The total study population consisted of 112 patients. Platelet aggregation inhibition was
variable for individuals and suboptimal for all agents, particularly in the periprocedural period.
Only with high-dose tirofiban, mean periprocedural platelet aggregation inhibition exceeded
80%. Angiographic parameters after PCI were not different between the groups. No
relationship was found between the level of platelet aggregation and parameters of PCI
success (Thrombolysis In Myocardial Infarction frame count and myocardial blush grade),
after combining the data from all four groups studied.
CONCLUSIONS Platelet aggregation inhibition in STEMI patients undergoing PCI, treated with antiplatelet
agents, is variable and suboptimal for all agents and dosages studied. Only with high-dose
tirofiban, mean periprocedural platelet aggregation inhibition exceeded 80%. However, no
relationship of platelet aggregation inhibition and angiographic outcome was found in this
patient cohort. (J Am Coll Cardiol 2004;44:1187–93) © 2004 by the American College of
Cardiology Foundationn
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lhe extent of pharmacologically induced platelet aggrega-
ion inhibition is an independent predictor of major cardiac
vents after percutaneous coronary intervention (PCI) (1,2).
he extent of platelet aggregation inhibition depends on
linical presentation and type and dosage of antiplatelet
gents (3–6). Patients with an acute coronary syndrome
ay have decreased response to antiplatelet agents (3,4),
nd tirofiban may be less effective than abciximab within 60
in after administration (5). Improving platelet aggregation
nhibition by increasing the bolus dose of the glycoprotein
GP) IIb/IIIa inhibitors has been described in patients
ndergoing elective or high-risk PCI and in patients with
From the *Isala Klinieken, location Weezenlanden, Department of Cardiology,
wolle, the Netherlands; †Isala Klinieken, location Weezenlanden, Department of
linical Chemistry, Zwolle, the Netherlands; ‡Thorax Centre, Department of
ardiology, Groningen, the Netherlands.
Manuscript received March 18, 2004; revised manuscript received May 13, 2004,occepted June 7, 2004.on–ST-segment elevation myocardial infarction (7–10).
his was not associated with an increased risk of major
leeding (11,12). In patients with ST-segment elevation
yocardial infarction (STEMI), routine dose of antiplatelet
gents may be associated with less effective platelet aggre-
ation inhibition.
We evaluated the extent of platelet aggregation inhibition
n patients with STEMI undergoing PCI, treated with
ifferent antiplatelet agents and dosages.
ETHODS
atient selection. Patients with STEMI who were candi-
ates for PCI within six h after onset of symptoms were
ncluded. Patients over 80 years of age, as well as women
50 years of age, patients who were treated with thrombo-
ytic therapy or GP IIb/IIIa inhibitors within the prior 24 h,
r patients on warfarin or acenocoumarol within the last 7
d
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Platelet Aggregation Inhibition in ST-Segment Elevation MI September 15, 2004:1187–93ays were excluded. Patients with a contraindication to GP
Ib/IIIa inhibitors, severe heart failure or cardiogenic shock
Killip class III or IV), and patients who were on hemodi-
lysis were also excluded. The study was conducted in
ccordance with the principles of the Declaration of Hel-
inki and with the laws and regulations applicable in the
etherlands. The local institutional review board approved
he protocol. As patients were enrolled in an emergency
ituation, before participation in the study (i.e., administra-
ion of study medication), oral informed consent was ob-
ained in all patients by a physician in the emergency room
n the presence of an independent witness (nurse), who
igned as a confirmation. Written informed consent was
equested after the PCI.
tudy protocol. The study was conducted as an open-label,
bservational, randomized, single-center study. It was de-
igned to compare the extent of platelet aggregation inhi-
ition in patients with STEMI who were treated with PCI
Abbreviations and Acronyms
GP  glycoprotein
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarctionFigure 1. Design oithin 6 h after onset of symptoms and who were treated
ith different antiplatelet agents. All patients were treated
ith 300 mg of clopidogrel orally before angiography.
atients were then randomized to treatment with abcix-
mab, tirofiban, high-dose tirofiban, or no GP IIb/IIIa
nhibitor (“control group”). In case the patient was allocated
o therapy with GP IIb/IIIa inhibitors, the GP IIb/IIIa
nhibitor bolus, immediately followed by the maintenance
nfusion, was administered after acute angiography, but
efore PCI. The study design is depicted in Figure 1.
omputerized randomization was performed in our emer-
ency room. All patients received a bolus of 5,000 IU of
nfractionated heparin intravenously together with 500 mg
f aspirin intravenously before the PCI. After the proce-
ure, all patients were treated with 100 mg of aspirin daily.
lopidogrel was continued for one month in a dose of 75
g orally. Abciximab was administered as a bolus of 0.25
g/kg intravenously followed by a maintenance infusion of
.125 g/kg/min (max 10 g/min) and continued for 12 h
fter the procedure. Normal dose tirofiban consisted of a
olus of 10 g/kg intravenously, followed by a maintenance
nfusion of 0.15 g/kg/min, and this was continued for 12 h
fter the PCI. In the patients who received high-dose
irofiban, a bolus of 25 g/kg was given. The maintenancef the study.
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ose group. Coronary angiography was performed accord-
ng to standard procedure as soon as possible after admis-
ion, followed by PCI of the infarct-related vessel.
ssessment of inhibition of platelet aggregation. Blood
amples to assess the extent of platelet aggregation inhibi-
ion were taken at four different time points: 1) after
dmission but before acute coronary angiography (baseline);
) immediately after PCI; 3) 1 h after PCI; and 4) 6 h after
CI.
Platelet aggregation inhibition was assessed on a routine
lood cell counter in the local laboratory of clinical chem-
stry with ethylenediamine tetraacetic acid as anticoagulant,
sing 20 M/l adenosine diphosphate as agonist (Sysmex K
500, Sysmex Corp., Kobe, Japan). The following proce-
ure was performed: a reference platelet count was per-
ormed on 1 ml of fresh whole blood in a tube containing
thylenediamine tetraacetic acid as the anticoagulant. The
ample was then passed through the cell counter, and the
latelet count was determined. This process was repeated
ith a second sample of 1 ml of fresh whole blood in a tube
ontaining both PPACK and 20 M/l ADP. In the
resence of ADP, platelets associate and aggregate. As the
ggregated platelets exceed the threshold limitations for
latelet size, they are no longer counted as individual
latelets. The ratio of the platelet count between the agonist
nd reference tubes was calculated as percent platelet aggre-
ation. Therefore, platelet aggregation inhibition could be
alculated by taking 100 (%) minus percent platelet aggre-
ation (%). In our laboratory (K.M., R.J.S.), we showed a
orrelation coefficient of 0.90 between the Sysmex K 4500
nd the ICHOR point-of-care platelet analyzer (Helena
aboratories, Beaumont, Texas) (13,14) to validate the
ysmex K 4500 platelet aggregation measurement.
efinitions. In-hospital reinfarction and mortality rates
ere assessed during hospital stay. Recurrent myocardial
nfarction was defined as a new increase in creatinine
inase-MB fraction of more than 3 the upper limit of
ormal, whether or not accompanied by chest pain and/or
lectrocardiographic changes and present in two separate
lood samples. Bleeding complications were closely moni-
ored clinically and by serial determinations of hemoglobin.
rolonged bleeding at the catheter insertion site, hemato-
as, or signs of any other blood loss were critically evalu-
ted. Major bleeding was defined as a fall in hemoglobin of
2.0 mmol/l and the need for transfusion of2 U of blood,
orrective surgery or both, or as bleeding that resulted in
ocumented intracranial or retroperitoneal hemorrhage.
inor bleeding was defined as a fall in hemoglobin of 2.0
mol/l without the need for a transfusion. A further
pecification was made in coronary artery bypass grafting
nd non-coronary artery bypass grafting-related major and
inor bleeding. Thrombocytopenia was defined as a throm-
ocyte count 100,000/mm3, whereas the patient had to
ave a thrombocyte count within the normal range on vdmission normal thrombocyte count between 150,000 to
50,000/mm3.
ngiographic core laboratory. All angiographic parame-
ers were analyzed by an independent core laboratory
Diagram BV, Zwolle, the Netherlands). The infarct-
elated vessel was identified by the core laboratory techni-
ian, based both on electrocardiographic localization of
schemia and angiographic appearance of the lesion. Grad-
ng of infarct-related vessel flow was performed according to
he Thrombolysis In Myocardial Infarction (TIMI) classi-
cation (15). In case of any doubt, a second investigator
ssessed flow of the infarct-related vessel, and consensus was
chieved in all cases. The corrected TIMI frame count and
he myocardial blush grade after angioplasty were defined as
reviously described (16,17).
tatistical analysis. Baseline characteristics were summa-
ized using descriptive statistics. Results are expressed as
ean values  SD. Differences between group means were
ested by analysis of variance. A chi-square method or
isher exact test was used to test differences between
roportions. The Fisher exact test was used if there was an
xpected cell value 5. Statistical significance was defined
s a p value 0.05.
In order to assess a possible relationship of platelet
ggregation inhibition and PCI success, the post-PCI
ggregation measurements from all patients were combined,
nd the mean extent of platelet aggregation inhibition
etween patients with successful versus unsuccessful PCI
as compared. Successful PCI was defined as TIMI flow
rade 3 and myocardial blush grade 3 or as a corrected
IMI frame count 14.
ESULTS
atient characteristics. Between August 1, 2002, and
ebruary 7, 2003, 119 patients were randomized before
ngiography. Baseline characteristics are shown in Table 1.
o significant differences were seen between the four
reatment groups. Mean age was 61 years, and 76% was
ale. Seven patients did not undergo a PCI, four patients
nderwent coronary artery bypass surgery, and three pa-
ients were treated conservatively. Therefore, the final study
opulation consisted of 112 patients.
latelet aggregation inhibition. Assessment of platelet
ggregation inhibition was performed in 89% to 94% of
atients at four different time points. At baseline, the mean
xtent of platelet aggregation inhibition was 21.0% in the
lopidogrel only, 16.9% in the abciximab, 15.1% in the
irofiban, and 15.9% in the high-dose tirofiban group.
mmediately after PCI, these values were 17.6%, 45.9%,
8.6%, and 84.2%, respectively. One hour after PCI, the
ean extent of platelet aggregation inhibition was 42.4%,
3.2%, 57.3%, and 74.5%. Finally, 6 h after PCI, the mean
latelet aggregation inhibition was 40.0%, 55.7%, 71.9%,
nd 64.1% for the four different groups. Results were highly
ariable for individual patients and suboptimal for all agents,
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ural period, the mean platelet aggregation inhibition was
ignificantly higher in the high-dose tirofiban regimen
ompared with any of the other regimens, and there was no
ignificant difference between the standard dose tirofiban
nd abciximab regimen. Only in the high-dose tirofiban
egimen, the mean periprocedural platelet aggregation in-
ibition exceeded 80%. With the standard dose tirofiban
nd abciximab regimen, the platelet aggregation inhibition
able 1. Baseline Characteristics of the Four Treatment Groups
C
(n  30)
ge (mean  SD) 59.8  11.3
ale gender (%) 80
eferral center (%) 47
ypertension (%) 27
iabetes (%) 13
moking (%) 60
ypercholesterolemia (%) 22
amily history (%) 41
revious MI (%) 3
revious PCI (%) 3
revious CABG (%) 0
revious CVA (%) 3
schemic time (mean [min] SD) 253  171
ime to first sample (mean [min] SD)* 46.3  31
The difference between C and C  A was statistically significant; however, this wa
n the emergency room and the glycoprotein IIb/IIIa inhibitors were given not earli
C  clopidogrel; CABG  coronary artery bypass grafting; CVA  cerebrovasc
irofiban; C  T  clopidogrel  tirofiban; MI  myocardial infarction; PCI  per
enter; Time to first sample  time from study drug bolus or clopidogrel loading do
pecimen).
able 2. Mean Platelet Aggregation Inhibition (%) SD at Fou
C C
(n  27) (n
aseline 21.0  23.8 16
fter PCI 17.6  22.3 45
h after PCI 42.4  33.8 53
h after PCI 40.0  31.6 55
aseline All com
fter PCI C versu
C versu
C versu
C  A
C  A
C  T
h after PCI C versu
C versu
C versu
C  A
C  A
C  T
h after PCI C versu
C versu
C versu
C  A
C  A
C  Tbbreviations as in Table 1.ncreased over the 6 h after PCI, but the difference was not
tatistically significant (standard dose tirofiban regimen: p
.058; abciximab regimen: p  0.720). For the high-dose
irofiban regimen, the platelet aggregation inhibition de-
reased over the 6 h after PCI, but also this difference was
ot statistically significant (p  0.085). The results of the
ssessment of the extent of platelet aggregation inhibition
or the four different treatment groups are shown in Table 2.
The TIMI flow after the procedure could be assessed in
C  A C  T C  HT
(n  30) (n  30) (n  29)
62.5  10.8 60.2  15.3 61.8  10.6
67 83 72
57 40 45
43 37 41
20 7 7
52 39 31
28 47 15
50 54 43
7 13 3
7 7 10
3 7 0
0 3 0
277  205 242  142 287  252
17.1  12.9 31.4  16.3 24.8  23.8
ly due to the fact that the oral dose of clopidogrel was given shortly after admission
after angiography.
ccident; C  A  clopidogrel  abciximab; C  HT  clopidogrel  high-dose
ous coronary intervention; Referral center  admitted in tertiary hospital via referral
latter for group treated with clopidogrel only) to first sample draw (i.e., “after PCI”
ferent Time Points
C  T C  HT
8) (n  29) (n  28)
2.8 15.1  22.1 15.9  20.2
9.8 58.6  28.9 84.2  16.1
6.4 57.3  26.9 74.5  16.7
5.5 71.9  17.3 64.1  22.2
p Value
ons NS
A 0.001
T  0.001
HT  0.001
s C  T NS
s C  HT  0.001
s C  HT 0.002
A NS
T NS
HT  0.001
s C  T NS
s C  HT 0.025
s C  HT NS
A NS
T  0.001
HT 0.006
s C  T NS
s C  HT NS
s C  HT NSs large
er than
ular a
cutane
se (ther Dif
 A
 2
.9  2
.9  2
.2  2
.7  2
paris
s C 
s C 
s C 
versu
versu
versu
s C 
s C 
s C 
versu
versu
versu
s C 
s C 
s C 
versu
versu
versu
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lush grade after PCI could be assessed in 107 of 112
atients (96%). The results of the angiographic parameters
fter PCI are shown in Table 3. No significant differences
ere seen between the four treatment groups for any of the
ssessed parameters. In the total group of 112 patients, no
elationship could be demonstrated between the extent of
latelet aggregation inhibition immediately after PCI and
ngiographic parameters of reperfusion (Table 3).
No patient suffered from reinfarction during hospital stay.
nly one patient died during hospitalization (high-dose
irofiban regimen). The total incidence of major and minor
leeding complications during admission was 13%. No
atients suffered from intracerebral hemorrhage or died
ecause of bleeding during admission. In the 12 patients
10%) with major bleeding, five cases were related to
oronary artery bypass grafting. In the remaining seven
atients with major bleeding, three patients (3%) suffered
rom a serious groin hematoma/bleeding. In three other
atients, no bleeding site could be found despite additional
iagnostic tests. One patient suffered from major bleeding
aused by a perforating gastric ulcer, for which urgent
bdominal surgery had to be performed. The total incidence
f thrombocytopenia during admission was 5%. A summary
f major and minor bleeding complications and the inci-
ence of thrombocytopenia for each treatment group is
iven in Table 4.
ISCUSSION
his study showed that, in the majority of patients with
TEMI undergoing PCI and treated with different anti-
latelet agents, platelet aggregation inhibition is subopti-
al. Furthermore, the data show that the extent of platelet
ggregation inhibition is highly variable in individual pa-
ients and varies considerably within each regimen at all
able 3. Angiographic Parameters and Relationship With IPA
C
(n  27)*
IMI flow grade 3 (%) 85
TFC  SD 22.4  10.1
BG 3 (%) 54
CTFC < 14
(n  18)
ean IPA ( SD) after PCI 60.6  34.6
ean IPA ( SD) 1 h after PCI 61.1  28.4
ean IPA ( SD) 6 h after PCI 65.4  21.4
MBG 3
(n  46)
ean IPA ( SD) after PCI 52.6  36.7
ean IPA ( SD) 1 h after PCI 54.7  30.7
ean IPA ( SD) 6 h after PCI 56.0  30.4
For all comparisons: p  NS.
CTFC  corrected TIMI frame count; IPA  platelet aggregation inhibition; M
bbreviations as in Table 1.ime points of assessment. Only with the high-dose tirofi- Tan regimen, the extent of periprocedural inhibition of
latelet aggregation reached a mean level 80%.
It, therefore, shows that, in high-risk patients with
TEMI undergoing PCI, in the setting of a large throm-
ogenic and inflammatory stimulus, a higher dose of GP
Ib/IIIa inhibitor may be necessary to achieve sufficiently
igh levels of inhibition. It is known that platelets are
ctivated mostly by agents like thrombin and collagen,
hich might result in an increase of the amount of activated
P IIb/IIIa receptors by as much as 50% (18). In patients
ith an acute STEMI, (occlusive) thrombus is present in
he vast majority of patients, and, therefore, these patients
re expected to have the highest extent of platelet activation,
s compared with patients with stable angina or patients
ith acute coronary syndromes without ST-segment eleva-
ion.
Our observations support the findings of previous smaller
tudies that found substantial interpatient variability in
 A C  T C  HT
 28)* (n  29)* (n  28)*
92 86 86
.2  8.9 28.2  18.9 24.2  16.0
32 35 52
CTFC > 14
(n  63) p Value
54.9  33.7 0.548
56.9  27.7 0.581
63.6  23.9 0.782
MBG < 3
(n  63) p Value
53.5  32.3 0.888
59.3  26.5 0.416
58.7  24.3 0.633
 myocardial blush grade; TIMI  Thrombolysis In Myocardial Infarction; other
able 4. Bleeding Complications and Thrombocytopenia
uring Admission
C C  A C  T C  HT
(n  30) (n  30) (n  30) (n  29)
ajor 2 0 8 2
CABG-related 1 0 3 1
inor 1 2 0 1
CABG-related 1 0 0 0
hrombocytopenia 2 1 2 1
CABG-related 1 0 0 1
Statistical Analysis According to the Incidence of Major Bleeding
 A versus C  T p  0.002
 A versus C p  0.237
 A versus C  HT p  0.237
 T versus C p  0.037
 T versus C  HT p  0.037
versus C  HT p  1.000
ABG-related  related to coronary artery bypass grafting; other abbreviations as inC
(n
23
BGable 1.
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Platelet Aggregation Inhibition in ST-Segment Elevation MI September 15, 2004:1187–93esponse to treatment with GP IIb/IIIa inhibitors (1,19–
1). Indirect evidence from several placebo-controlled trials
f GP IIb/IIIa inhibitors in PCI has suggested the impor-
ance of achieving and maintaining a specific level of platelet
nhibition to minimize thrombotic complications (22). In
ur study, only a very small number of patients had levels of
nhibition of platelet aggregation 95%, the level that is
ssumed to be associated with a decrease in the incidence of
ajor cardiac events after PCI (1). The “debate on the
osage” continues, as it is still unknown which “target” level
s needed for patients with STEMI undergoing PCI.
lthough a higher level of periprocedural platelet aggrega-
ion inhibition was observed in the high-dose tirofiban
egimen, this was not associated with a better angiographic
utcome. The other way around, no relationship was found
etween success of the PCI (TIMI frame count 14 or
yocardial blush grade 3) and the extent of platelet aggre-
ation inhibition when the data of all 112 patients were
ombined. Therefore, it remains to be studied whether
latelet aggregation testing is clinically useful and whether
urther dose-adjustment of antiplatelet agents will further
mprove angiographic or clinical outcome.
Furthermore, this study showed that platelet aggregation
nhibition increases over time after the oral administration
f 300 mg of clopidogrel. However, only at 1 h after PCI,
measurable increase in platelet inhibition was found. This
mplicates that, in patients with acute myocardial infarction
n which the PCI should be performed as soon as possible,
n oral dose of clopidogrel alone might not give sufficient
latelet aggregation inhibition during the PCI procedure.
revious studies showed that clopidogrel at a loading dose
f 600 mg results in sufficient platelet aggregation inhibition
ithin 2 h after ingestion; however, whether these results
re reproducible in patients with an acute myocardial
nfarction remains to be evaluated (23).
Only a few patients suffered from a major bleeding
omplication or a thrombocytopenia during admission, and,
lthough the rate of major complications is higher in the
tandard dose tirofiban group, these complications were not
pecifically related to the high-dose tirofiban regimen in
articular. Our results are in accordance with earlier obser-
ations during treatment with (high-dose bolus) tirofiban
11,12).
tudy limitations. Platelet aggregation inhibition was as-
essed using one evaluation method. Although we validated
he blood cell counter, by showing a correlation coefficient
f 0.90 with the ICHOR point-of-care platelet analyzer
Helena Laboratories), our results may not be directly
omparable with the absolute levels of platelet aggregation
nhibition seen in the AU-Assessing Ultegra (GOLD) trial,
n which the ultegra rapid platelet function analyser (Accu-
etrics Inc., San Diego, California) was used for evaluation
f platelet aggregation inhibition (1,13,14,24). However,
his does not affect differences in measurements of platelet
ggregation inhibition between the four treatment groups.
econdly, the sample size in our study was too small toemonstrate differences in outcome. Finally, we evaluated
wo different tirofiban dose regimens and no other abcix-
mab dose regimen than the currently used dosage scheme.
This study assessed periprocedural platelet aggregation
nhibition only at one time point (immediately after PCI).
o information is available on platelet inhibition just before
CI, or between 25 and 85 min after the administration of
tudy drug, which is a shortcoming of the study.
onclusions. The extent of platelet aggregation inhibition
n patients with STEMI undergoing PCI and treated with
ifferent antiplatelet agents is highly variable and subopti-
al for all agents and dosages studied. Only with the
igh-dose tirofiban regimen, the mean periprocedural level
f platelet aggregation inhibition exceeded 80%. However,
o difference in angiographic outcome between the groups
as found, and no relationship was found between the level
f platelet aggregation inhibition and angiographic outcome
hen the data of all groups were combined. Therefore,
urther studies should be performed to assess whether dose
djustment or combination therapy of different antiplatelet
gents will further improve clinical outcome.
eprint requests and correspondence: Dr. Arnoud W. J. van ’t Hof,
sala Klinieken, location Weezenlanden, Groot Wezenland 20, 8011
W Zwolle, the Netherlands. E-mail: v.r.c.derks@isala.nl.
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